View clinical trials related to Neoplasm Malignant.
Filter by:Primary Objective: - To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously every 3 weeks in Chinese patients with solid tumors. Secondary Objectives: - To assess the safety profile of intravenous (IV) aflibercept when administered in combination with docetaxel - To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in combination - To make a preliminary assessment of antitumor effects of the combination of docetaxel plus aflibercept in patients with evaluable disease - To evaluate the immunogenicity of IV aflibercept - To measure endogenous free Vascular Endothelial Growth Factor (VEGF)
Primary Objectives: - To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment - To determine the pharmacokinetics (PKs) of Cabazitaxel in patients with varying degrees of hepatic impairment - To correlate PK variables with pharmacodynamic (PD) safety parameters in order to guide prescribers with regard to dosing in this patient population - To assess the effect of cabazitaxel at recommended dose of 25mg/m^2 on CYP3A enzyme activity using midazolam as probe in an additional cohort of cancer patients with normal hepatic function.
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.